Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Envoy Medical (COCH) over the last 4 years, with Q2 2025 value amounting to -$1000.0.

  • Envoy Medical's Cash from Investing Activities rose 9987.34% to -$1000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $527000.0, marking a year-over-year increase of 13433.22%. This contributed to the annual value of -$980000.0 for FY2024, which is 54052.29% down from last year.
  • Per Envoy Medical's latest filing, its Cash from Investing Activities stood at -$1000.0 for Q2 2025, which was up 9987.34% from -$6000.0 recorded in Q1 2025.
  • In the past 5 years, Envoy Medical's Cash from Investing Activities registered a high of $534000.0 during Q4 2024, and its lowest value of -$790000.0 during Q2 2024.
  • For the 4-year period, Envoy Medical's Cash from Investing Activities averaged around -$107363.6, with its median value being -$41000.0 (2022).
  • Examining YoY changes over the last 5 years, Envoy Medical's Cash from Investing Activities showed a top increase of 264285.71% in 2024 and a maximum decrease of 708181.82% in 2024.
  • Quarter analysis of 4 years shows Envoy Medical's Cash from Investing Activities stood at -$41000.0 in 2022, then soared by 48.78% to -$21000.0 in 2023, then skyrocketed by 2642.86% to $534000.0 in 2024, then plummeted by 100.19% to -$1000.0 in 2025.
  • Its Cash from Investing Activities stands at -$1000.0 for Q2 2025, versus -$6000.0 for Q1 2025 and $534000.0 for Q4 2024.